TapImmune Commences Trading on the Nasdaq Capital Market

Jacksonville, Fla. – November 8, 2016 – TapImmune, Inc., (NASDAQ: TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has commenced trading on The Nasdaq Capital Market from the opening of market today. The company’s…

Details

TapImmune Approved for Listing on the Nasdaq Capital Market

JACKSONVILLE, Fla., Nov. 3, 2016 /PRNewswire/ — TapImmune, Inc., (TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has been approved to begin trading on The Nasdaq Capital Market. The company’s common stock will…

Details

TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

JACKSONVILLE, Florida, September 15, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today that its Board of Directors has approved a 1-for-12 reverse stock split of the Company’s authorized, issued, and outstanding common…

Details